<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Valbenazine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Valbenazine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Valbenazine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="112803" href="/d/html/112803.html" rel="external">see "Valbenazine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58624041"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Depression and suicidal ideation and behavior in patients with Huntington disease:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">VMAT2 inhibitors, including valbenazine, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington disease. Anyone considering the use of valbenazine must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence of worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician.</p>
<p style="text-indent:-2em;margin-left:2em;">Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington disease.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50023907"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ingrezza</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F49912952"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Central Monoamine-Depleting Agent;</li>
<li>
                        Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F49945375"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b7fa645-6203-4543-8c77-491ee5c33ad0">Chorea associated with Huntington disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chorea associated with Huntington disease</b>
<b>: Oral: </b>Initial: 40 mg once daily; increase dose in 20 mg increments every 2 weeks to a target dose of 80 mg once daily. Continuation of 40 to 60 mg once daily may be considered for some patients based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37210099','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37210099','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b2d9655-3745-4090-b9e4-e090f9c7caad">Tardive dyskinesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tardive dyskinesia: Oral:</b> Initial: 40 mg once daily; after 1 week, increase to 80 mg once daily. Continuation of 40 or 60 mg once daily may be considered for some patients based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31688452','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31688452','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991985"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Mild to severe impairment: No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50989220"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (Child-Pugh class B or C): 40 mg once daily</p></div>
<div class="block dot drugH1Div" id="F58624098"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Depression or suicidality, unresolving: Consider discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reaction (eg, angioedema, rash, shortness of breath, urticaria): Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Neuroleptic malignant syndrome: Immediately discontinue valbenazine; monitor and manage symptoms and concomitant complications. If valbenazine therapy is reinitiated after recovery, monitor for signs of recurrence.</p>
<p style="text-indent:-2em;margin-left:2em;">Parkinsonism: Reduce dose; discontinuation of therapy may be necessary.</p></div>
<div class="block doe drugH1Div" id="F49945376"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F49949630"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Drowsiness (≤19%), fatigue (≤14%), lethargy (≤19%), sedated state (≤19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (8%), urticaria (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose (≥1%), weight gain (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (5%), nausea (5%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (≤4%), akathisia (≤6%), anxiety (≥1%), balance impairment (≤4%), depressed mood (≤5%), depression (≤5%), dizziness (≤4%), drooling (≥1%), extrapyramidal reaction (≥1%), falling (≤4%), insomnia (6%; including middle insomnia), parkinsonism (3% to 5%), restlessness (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (2%), back pain (5%), dyskinesia (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory tract infection (≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperprolactinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuroleptic malignant syndrome</p></div>
<div class="block coi drugH1Div" id="F49912955"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, rash, urticaria, symptoms consistent with angioedema [eg, swelling of the face, lips, and mouth]) to valbenazine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F49948348"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression/Suicidal ideation: Vesicular monoamine transport inhibitors, including valbenazine, have been associated with depression and suicidal thoughts and behavior. In a pooled analysis of two 6-week trials and a 42-week extension trial, 96.5% (N = 113) of patients with tardive dyskinesia who reported no suicidal ideation at baseline continued to have no suicidal ideation at any time during the study; however, 4 patients (2 on placebo, 2 on valbenazine) reported a shift in their Columbia-Suicide Severity Rating Scale score to suicidal thoughts/ideation (McIntyre 2019). In patients with Huntington disease, depression or depressed mood was reported in 4.7% of patients receiving valbenazine (versus 1.6% placebo) in a randomized controlled trial; suicidal ideation (7.3%) and suicide attempts (2.4%) were also reported in an open-label extension trial.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity, including angioedema (which may be fatal) of the eyelids, glottis, larynx, and lips, have occurred after the first dose or subsequent doses of valbenazine. Rash, shortness of breath, and urticaria were also reported in patients with Huntington disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuroleptic malignant syndrome: Vesicular monoamine transport inhibitors, including valbenazine, may be associated with neuroleptic malignant syndrome; signs/symptoms may include acute kidney failure, altered mental status, autonomic instability (eg, cardia dysrhythmia, diaphoresis, irregular pulse or BP, tachycardia), elevated creatine phosphokinase, fever, muscle rigidity, myoglobinuria, and rhabdomyolysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinsonism: Cases of parkinson-like symptoms (eg, falls, gait disturbances, tremor, drooling, hypokinesia), some severe requiring hospitalization, have been reported. Development of these symptoms in patients with Huntington disease may be difficult to differentiate from progression of the underlying disease; drug-induced parkinsonism may cause more functional disability than untreated chorea in Huntington disease. Onset of severe symptoms in patients receiving treatment for tardive dyskinesia occurs most commonly within 2 weeks of the start of therapy or a dose increase; may resolve with discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: QT prolongation may occur but may be clinically insignificant when valbenazine is administered within the recommended dosage range. Avoid use in patients with congenital QT prolongation or a history of cardiac arrhythmias associated with prolonged QT.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate or severe hepatic impairment; dose reduction is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Huntington disease: Underlying chorea may improve over time in some patients, thereby decreasing the need for therapy. Reevaluate patients' need for treatment by periodically assessing the effect on chorea and possible adverse effects (Hermann 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2D6 poor metabolizers: CYP2D6 poor metabolizes may have increased levels of primary drug metabolites, which may increase the risk of adverse effects (eg, QT interval prolongation); dosage reduction is recommended.</p></div>
<div class="block foc drugH1Div" id="F50023908"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as tosylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ingrezza: 40 mg, 60 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ingrezza: 80 mg [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Therapy Pack, Oral, as tosylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ingrezza: Valbenazine 40 mg (7s) and valbenazine 80 mg (21s) [28 day therapy pack] (28 ea) [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p></div>
<div class="block geq drugH1Div" id="F50023906"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F50027562"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Ingrezza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 &amp; 80 mg (per each): $353.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ingrezza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $300.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $330.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $330.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F49945059"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food.</p></div>
<div class="block use drugH1Div" id="F49912954"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chorea associated with Huntington disease: </b>Treatment of adults with chorea associated with Huntington disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Tardive dyskinesia:</b> Treatment of adults with tardive dyskinesia.</p></div>
<div class="block cyt drugH1Div" id="F49944680"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F49944677"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Valbenazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Valbenazine. Management: Reduce valbenazine dose to 40 mg once daily when combined with a strong CYP2D6 inhibitor. Monitor for increased valbenazine effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Valbenazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine. Management: Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Valbenazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Valbenazine may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors may diminish the therapeutic effect of Levodopa-Foslevodopa.  Management: Consider alternatives to the coadministration of levodopa and vesicular monoamine transporter 2 (VMAT2) inhibitors. If combined, monitor for reduced levodopa efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Valbenazine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Valbenazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Valbenazine.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F49948929"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies</p></div>
<div class="block brc drugH1Div" id="F49948930"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if valbenazine is present in breast milk. Based on data from animal studies, the manufacturer does not recommend breastfeeding during therapy or until 5 days after the last dose.</p></div>
<div class="block mop drugH1Div" id="F49945061"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">EKG (for patients at risk for QT prolongation; prior to dose increase); signs/symptoms of suicidal ideation.</p></div>
<div class="block pha drugH1Div" id="F49948352"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The mechanism of action of valbenazine in the treatment of tardive dyskinesia and chorea in patients with Huntington disease is unknown, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release. Valbenazine and its active metabolite have no appreciable binding affinity for VMAT1 or dopaminergic, serotonergic, adrenergic, histaminergic or muscarinic receptors.</p></div>
<div class="block phk drugH1Div" id="F49946717"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: High-fat meals decrease C<sub>max</sub> by 47% and AUC by 13%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 92 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Valbenazine: &gt;99%; Active metabolite: ~64%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively metabolized by hydrolysis to form active metabolite ([+]-α-HTBZ) and by oxidative metabolism, primarily by CYP3A4/5, to form monooxidized valbenazine and other minor metabolites. The active metabolite is further metabolized in part by CYP2D6.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~49%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 15 to 22 hours (valbenazine and active metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Valbenazine: 0.5 to 1 hours; Active metabolite: 4 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~60%, primarily as inactive metabolites); feces (~30%, primarily as inactive metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54096776"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ingrezza</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dysval</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ingrezza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37210099">
<a name="37210099"></a>Furr Stimming E, Claassen DO, Kayson E, et al; Huntington Study Group KINECT-HD Collaborators. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurol</i>. 2023;22(6):494-504. doi:10.1016/S1474-4422(23)00127-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valbenazine-drug-information/abstract-text/37210099/pubmed" id="37210099" target="_blank">37210099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25620691">
<a name="25620691"></a>Hermann A, Walker RH. Diagnosis and treatment of chorea syndromes. <i>Curr Neurol Neurosci Rep</i>. 2015;15(2):514. doi:10.1007/s11910-014-0514-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valbenazine-drug-information/abstract-text/25620691/pubmed" id="25620691" target="_blank">25620691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ingrezza.1">
<a name="Ingrezza.1"></a>Ingrezza (valbenazine) [prescribing information]. San Diego, CA: Neurocrine Biosciences Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31688452">
<a name="31688452"></a>Marder SR, Singer C, Lindenmayer JP, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. <i>J Clin Psychopharmacol</i>. 2019;39(6):620-627. doi:10.1097/JCP.0000000000001111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valbenazine-drug-information/abstract-text/31688452/pubmed" id="31688452" target="_blank">31688452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30583148">
<a name="30583148"></a>McIntyre RS, Calabrese JR, Nierenberg AA, et al. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. <i>J Affect Disord</i>. 2019;246:217-223. doi:10.1016/j.jad.2018.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valbenazine-drug-information/abstract-text/30583148/pubmed" id="30583148" target="_blank">30583148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li></ol></div><div id="topicVersionRevision">Topic 112668 Version 116.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
